JP2016515098A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016515098A5 JP2016515098A5 JP2015560285A JP2015560285A JP2016515098A5 JP 2016515098 A5 JP2016515098 A5 JP 2016515098A5 JP 2015560285 A JP2015560285 A JP 2015560285A JP 2015560285 A JP2015560285 A JP 2015560285A JP 2016515098 A5 JP2016515098 A5 JP 2016515098A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- dimethyl
- carbazole
- carboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CCCC(*)(*C)N Chemical compound CCCC(*)(*C)N 0.000 description 4
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361769996P | 2013-02-27 | 2013-02-27 | |
| US61/769,996 | 2013-02-27 | ||
| US14/190,477 US9492460B2 (en) | 2013-02-27 | 2014-02-26 | Carbazole compounds useful as bromodomain inhibitors |
| US14/190,477 | 2014-02-26 | ||
| PCT/US2014/018820 WO2014134232A1 (en) | 2013-02-27 | 2014-02-27 | Carbazole compounds useful as bromodomain inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016515098A JP2016515098A (ja) | 2016-05-26 |
| JP2016515098A5 true JP2016515098A5 (enExample) | 2017-03-30 |
| JP6395731B2 JP6395731B2 (ja) | 2018-09-26 |
Family
ID=50382555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015560285A Active JP6395731B2 (ja) | 2013-02-27 | 2014-02-27 | ブロモドメイン阻害剤として有用なカルバゾール化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9492460B2 (enExample) |
| EP (1) | EP2961748B1 (enExample) |
| JP (1) | JP6395731B2 (enExample) |
| CN (1) | CN105008352B (enExample) |
| BR (1) | BR112015020389A8 (enExample) |
| CA (1) | CA2902737A1 (enExample) |
| EA (1) | EA027345B1 (enExample) |
| ES (1) | ES2669189T3 (enExample) |
| MX (1) | MX2015010921A (enExample) |
| WO (1) | WO2014134232A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015508414A (ja) | 2012-01-12 | 2015-03-19 | イエール ユニバーシティ | Ｅ３ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法 |
| US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
| US9271978B2 (en) | 2012-12-21 | 2016-03-01 | Zenith Epigenetics Corp. | Heterocyclic compounds as bromodomain inhibitors |
| JP6404838B2 (ja) | 2013-02-27 | 2018-10-17 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ブロモドメイン阻害剤として有用なカルバゾール化合物 |
| JP6401773B2 (ja) * | 2013-03-11 | 2018-10-10 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | Ｂｅｔブロモドメイン阻害剤およびこれを用いる治療方法 |
| US9227985B2 (en) | 2013-03-15 | 2016-01-05 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| WO2015004533A2 (en) | 2013-06-21 | 2015-01-15 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| SG11201510409QA (en) | 2013-06-21 | 2016-01-28 | Zenith Epigenetics Corp | Novel bicyclic bromodomain inhibitors |
| EP3019502B1 (en) | 2013-07-08 | 2017-05-17 | Incyte Holdings Corporation | Tricyclic heterocycles as bet protein inhibitors |
| AU2014298051B2 (en) | 2013-07-31 | 2018-11-15 | Zenith Epigenetics Ltd. | Novel quinazolinones as bromodomain inhibitors |
| US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
| WO2015081189A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
| HUE054183T2 (hu) * | 2013-12-24 | 2021-08-30 | Bristol Myers Squibb Co | Triciklusos vegyület rákellenes szerekként |
| US9458156B2 (en) | 2014-12-23 | 2016-10-04 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| JP2017511801A (ja) | 2014-02-28 | 2017-04-27 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | ＢＥＴブロモドメイン阻害剤としての９Ｈ−ピリミド［４，５−ｂ］インドールおよび関連類似体 |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| MY180775A (en) | 2014-04-23 | 2020-12-09 | Incyte Corp | 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins |
| BR112016026046A8 (pt) | 2014-05-08 | 2021-07-20 | Oncoethix Gmbh | uso de compostos de tienotriazolodiazepina |
| US9527864B2 (en) | 2014-09-15 | 2016-12-27 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
| KR20170055549A (ko) * | 2014-10-02 | 2017-05-19 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 화합물 |
| WO2016087936A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Corp. | Substituted pyridinones as bromodomain inhibitors |
| WO2016087942A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Corp. | Substituted pyridines as bromodomain inhibitors |
| CN107207474B (zh) | 2014-12-11 | 2021-05-07 | 恒翼生物医药科技(上海)有限公司 | 被取代的杂环作为溴结构域抑制剂 |
| CA2966450A1 (en) | 2014-12-17 | 2016-06-23 | Olesya KHARENKO | Inhibitors of bromodomains |
| JP7269731B2 (ja) | 2015-03-18 | 2023-05-09 | アルビナス・オペレーションズ・インコーポレイテッド | 標的タンパク質の分解向上のための化合物および方法 |
| GB201504694D0 (en) | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
| EP3294736B1 (en) | 2015-05-11 | 2020-07-22 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| US9725449B2 (en) | 2015-05-12 | 2017-08-08 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| EP3307740B1 (en) | 2015-05-12 | 2019-12-18 | Bristol-Myers Squibb Company | 5h-pyrido[3,2-b]indole compounds as anticancer agents |
| CN108137507A (zh) | 2015-07-10 | 2018-06-08 | 阿尔维纳斯股份有限公司 | 基于mdm2的蛋白水解调节剂和相关的使用方法 |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| WO2017075377A1 (en) | 2015-10-29 | 2017-05-04 | Incyte Corporation | Amorphous solid form of a bet protein inhibitor |
| WO2017165139A1 (en) | 2016-03-25 | 2017-09-28 | St. Jude Children's Research Hospital | 1,4,5-substituted 1,2,3-triazole analogues as antagonists of the pregnane x receptor |
| ES3037659T3 (en) | 2016-03-30 | 2025-10-03 | Wisconsin Alumni Res Found | Methods and compositions for modulating frataxin expression |
| US20170281784A1 (en) | 2016-04-05 | 2017-10-05 | Arvinas, Inc. | Protein-protein interaction inducing technology |
| KR102643344B1 (ko) | 2016-06-20 | 2024-03-07 | 인사이트 코포레이션 | Bet 저해제의 결정질 고체 형태 |
| EP3577109A4 (en) | 2017-01-31 | 2020-11-18 | Arvinas Operations, Inc. | CEREMONY LIGANDS AND BIFUNCTIONAL COMPOUNDS CONTAINING THEM |
| WO2018183679A1 (en) | 2017-03-29 | 2018-10-04 | Wisconsin Alumni Research Foundation | Methods and compositions for modulating gene expression |
| JP2021512153A (ja) | 2018-01-26 | 2021-05-13 | イエール ユニバーシティ | タンパク質分解のイミド系モジュレーターおよび使用方法 |
| EP4077309A1 (en) | 2019-12-19 | 2022-10-26 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| CN111809182B (zh) * | 2020-07-08 | 2025-04-18 | 江苏和达电子科技有限公司 | 一种用于铜/钼（铌）/igzo膜层的刻蚀液及其制备方法和应用 |
| US12016847B2 (en) | 2021-03-12 | 2024-06-25 | Bristol-Myers Squibb Company | Methods of treating prostate cancer |
| CA3255952A1 (en) * | 2022-05-20 | 2023-11-23 | University Of Puerto Rico | 1,2,3-Triazoles 1,4,5-Trisubstitutes and their uses |
| WO2025049555A1 (en) | 2023-08-31 | 2025-03-06 | Oerth Bio Llc | Compositions and methods for targeted inhibition and degradation of proteins in an insect cell |
| US20260092058A1 (en) | 2024-09-30 | 2026-04-02 | St. Jude Children's Research Hospital, Inc. | Small Molecule Degraders and Fluorescent Probes of PXR |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9310635D0 (en) * | 1993-05-21 | 1993-07-07 | Glaxo Group Ltd | Chemical compounds |
| US6177440B1 (en) | 1996-10-30 | 2001-01-23 | Eli Lilly And Company | Substituted tricyclics |
| WO2002000255A1 (en) * | 2000-06-29 | 2002-01-03 | Shionogi & Co., Ltd. | Remedies for cancer |
| US6933313B2 (en) * | 2001-03-28 | 2005-08-23 | Eli Lilly And Company | Substituted carbazoles as inhibitors of sPLA2 |
| US6602619B2 (en) | 2001-10-19 | 2003-08-05 | Lightronik Technology Inc. | Organic EL device |
| JP2007509045A (ja) | 2003-10-18 | 2007-04-12 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 尿失禁および関連疾患の処置用のｇａｂａアゴニストとしての５−置換２−（フェニルメチル）チオ−４−フェニル−４ｈ−１，２，４−トリアゾール誘導体および関連化合物 |
| WO2006012310A2 (en) * | 2004-06-25 | 2006-02-02 | Genzyme Corporation | Carbazole derivatives for treating polycystic kidney disease |
| CN102325752B (zh) * | 2008-12-19 | 2015-02-04 | 百时美施贵宝公司 | 咔唑和咔啉激酶抑制剂 |
| EP2496580B1 (en) * | 2009-11-05 | 2013-12-11 | GlaxoSmithKline LLC | Benzodiazepine bromodomain inhibitor |
| US8916593B2 (en) | 2010-05-04 | 2014-12-23 | Pfizer Inc. | Alkoxy-substituted 2-aminopyridines as ALK inhibitors |
| JP5623996B2 (ja) | 2010-09-21 | 2014-11-12 | 株式会社半導体エネルギー研究所 | カルバゾール誘導体 |
| JP5842630B2 (ja) | 2011-03-16 | 2016-01-13 | 株式会社リコー | カルバゾール誘導体、及び半導体ナノ結晶 |
| WO2012150826A1 (en) * | 2011-05-03 | 2012-11-08 | Rohm And Haas Electronic Materials Korea Ltd. | Novel organic electroluminescent compounds and an organic electroluminescent device using the same |
| UA115576C2 (uk) * | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
-
2014
- 2014-02-26 US US14/190,477 patent/US9492460B2/en active Active
- 2014-02-27 CN CN201480010613.1A patent/CN105008352B/zh active Active
- 2014-02-27 MX MX2015010921A patent/MX2015010921A/es unknown
- 2014-02-27 EA EA201591591A patent/EA027345B1/ru not_active IP Right Cessation
- 2014-02-27 JP JP2015560285A patent/JP6395731B2/ja active Active
- 2014-02-27 BR BR112015020389A patent/BR112015020389A8/pt not_active Application Discontinuation
- 2014-02-27 EP EP14712815.1A patent/EP2961748B1/en active Active
- 2014-02-27 ES ES14712815.1T patent/ES2669189T3/es active Active
- 2014-02-27 CA CA2902737A patent/CA2902737A1/en not_active Abandoned
- 2014-02-27 WO PCT/US2014/018820 patent/WO2014134232A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI579284B (zh) | 咪唑并吡咯啶酮化合物 | |
| AU2008236562B2 (en) | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha | |
| JP2025508702A (ja) | キナゾリン化合物、及び変異ｋｒａｓタンパク質の阻害剤としてのその使用 | |
| JP2024517695A (ja) | 複素環式化合物及び使用方法 | |
| RU2665036C2 (ru) | Гетероароматические соединения-модуляторы фосфоинозидит-3-киназы и способы применения | |
| JP6935415B2 (ja) | ２−アミノ−Ｎ−［７−メトキシ−２，３−ジヒドロイミダゾ−［１，２−ｃ］キナゾリン−５−イル］ピリミジン−５−カルボキサミド類 | |
| RU2672910C9 (ru) | Гетероароматические соединения как модуляторы фосфоинозитид-3-киназы | |
| EP3310779A1 (en) | Compounds and compositions for inhibiting the activity of shp2 | |
| JP2016537384A5 (enExample) | ||
| JP2017524702A5 (enExample) | ||
| KR20010050223A (ko) | Ｃｒｆ 길항제 및 관련 조성물의 용도 | |
| JP2017505762A5 (enExample) | ||
| WO2019071147A1 (en) | INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD | |
| JP2012532131A5 (enExample) | ||
| JP2016523974A5 (enExample) | ||
| JP2014518544A5 (enExample) | ||
| RU2014152790A (ru) | Пирролопиразоновые ингибиторы танкиразы | |
| EP3274344A1 (en) | Formylated n-heterocyclic derivatives as fgfr4 inhibitors | |
| JP2016509056A5 (enExample) | ||
| RU2014126750A (ru) | Ингибиторы тирозинкиназы брутона | |
| RU2019108717A (ru) | Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов | |
| JP2021514011A5 (enExample) | ||
| FI3478284T3 (fi) | Yhdisteitä ja koostumuksia syövän hoitoon | |
| WO2016193955A1 (en) | Combinations of kinase inhibitors for treating colorectal cancer | |
| JP2025538452A (ja) | ９型ホスホジエステラーゼの阻害による特定の神経精神障害の治療または予防におけるセロトニン作動性幻覚薬の効力の増強 |